Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
A Randomized Phase 2 Study of Hypofractionated Concurrent Chemoradiotherapy Combined With Tislelizumab and Surufatinib in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 2
Contacten en locaties
Studiecontact
Studiecontact
- Naam: DaQuan Wang, MD
- Telefoonnummer: +862087343031
- E-mail: wangdq@sysucc.org.cn
Studie Locaties
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Werving
- Sun Yat-sen University Cancer Center
-
Contact:
- Hui Liu, Doctor
- Telefoonnummer: +862087343031
- E-mail: liuhuisysucc@126.com
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Males or females aged 18 to 75 years or older;
- Patients must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC);
- Unresectable Stage III disease according to AJCC 8th staging system;
- Negative for known driver gene mutations;
- Newly diagnosed patients or patients treated with ≤ 4 cycles of chemotherapy combined with or without immunotherapy;
- Expected survival ≥ 12 weeks;
- WHO Performance Status (PS) score of 0 or 1;
- Female subjects must not be breastfeeding;
- Women of childbearing potential (WOCBP) must agree to use contraception during the study treatment and for 5 months after the last dose of study drug (i.e., 30 days [one ovulation cycle] plus approximately five half-lives of the study drug);
- Adequate organ and bone marrow function as defined by the following criteria:
- Forced Expiratory Volume in 1 second (FEV1) ≥ 800 mL;
- Absolute neutrophil count ≥ 1.5 × 10⁹/L;
- Platelets ≥ 100 × 10⁹/L;
- Hemoglobin ≥ 9.0 g/dL;
- Creatinine clearance ≥ 50 mL/min as calculated by the Cockcroft-Gault formula (Cockcroft and Gault, 1976);
- Serum bilirubin ≤ 1.5 × upper limit of normal (ULN);
- AST and ALT ≤ 2.5 × ULN.
Exclusion Criteria:
- Concurrent enrolment in another clinical study, unless it is an observational(non-interventional) clinical study;
- Mixed small cell and non-small cell lung cancer histology;
- Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access;
- Active or prior documented autoimmune disease within the past 2 years;
- Active or prior documented inflammatory bowel disease (eg. Crohn's disease, ulcerative colitis);
- History of primary immunodeficiency;
- History of organ transplant that requires therapeutic immunosuppression;
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent;
- Known history of tuberculosis;
- History of another primary malignancy within 5 years prior to starting treatment, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the disease under study;
- Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Study group A
Patients will receive hypofractionated thoracic radiotherapy with concurrent chemotherapy, combined with tislelizumab and surufatinib during radiotherapy.
Patients who achieve complete response, partial response, or stable disease after chemoradiotherapy will receive consolidation therapy with tislelizumab and surufatinib for up to one year.
|
Split-course hypofractionated thoracic radiotherapy
Weekly nab-paclitaxel and cisplatin during radiotherapy
Tislelizumab 200mg every three weeks during and following radiotherapy
Surufatinib during and following radiotherapy
|
|
Experimenteel: Study group B
Patients will receive hypofractionated thoracic radiotherapy with concurrent chemotherapy, combined with tislelizumab during radiotherapy.
Patients who achieve complete response, partial response, or stable disease after chemoradiotherapy will receive consolidation therapy with tislelizumab for up to one year.
|
Split-course hypofractionated thoracic radiotherapy
Weekly nab-paclitaxel and cisplatin during radiotherapy
Tislelizumab 200mg every three weeks during and following radiotherapy
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-free survival
Tijdsspanne: 18-month
|
The time from randomization to the first documented disease progression or death from any cause, whichever occurs first.
|
18-month
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall survival
Tijdsspanne: 18-month
|
The time from randomization to death from any cause, censored at the last follow-up date.
|
18-month
|
|
Treatment related toxicity
Tijdsspanne: 18-month
|
Graded by CTCAE 5.0
|
18-month
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- A2025-007
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .